Understanding patient preferences for chemotherapy in breast cancer
Patients' Preferences for Adjuvant or Neoadjuvant Chemotherapy in Breast Cancer
European Institute of Oncology · NCT06332976
This study is trying to understand what women with breast cancer expect from chemotherapy in terms of survival and side effects by talking to them at different points during their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 450 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | European Institute of Oncology (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Milan) |
| Trial ID | NCT06332976 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather insights from women undergoing adjuvant or neoadjuvant chemotherapy for breast cancer regarding the survival benefits they expect from treatment. It evaluates patient perspectives on survival rate trade-offs and survival time trade-offs through interviews conducted at three different stages: before starting chemotherapy, during treatment, and after completion. The study seeks to understand whether patients' expectations align with realistic outcomes, considering the side effects of chemotherapy on their quality of life.
Who should consider this trial
Good fit: Ideal candidates include women with early or locally advanced breast cancer who are candidates for or currently receiving chemotherapy.
Not a fit: Patients who do not speak Italian or those who are not undergoing chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help tailor chemotherapy approaches to better align with patient expectations and improve their quality of life.
How similar studies have performed: While there have been studies on patient preferences in cancer treatment, this specific approach focusing on survival trade-offs in breast cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with early or locally advanced breast cancer * Patients candidate to adjuvant/neoadjuvant chemotherapy or patients who are receiving adjuvant/neoadjuvant chemotherapy or patients who received adjuvant/neoadjuvant chemotherapy * Sufficient literacy in Italian to complete the questionnaires * Patients must provide signed, written or advanced electronic signature (AES or AdES), informed consent Exclusion Criteria: * None
Where this trial is running
Milan
- European Institute of Oncology — Milan, Italy (RECRUITING)
Study contacts
- Principal investigator: Emilia Montagna, MD — European Institute of Oncology
- Study coordinator: Emilia Montagna, MD
- Email: emilia.montagna@ieo.it
- Phone: +390257489970
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Female Breast Cancer, Early breast cancer, Locally advanced breast cancer